Ad26.Mos4.HIV
AXP000174.1 · Vaccine
- Platform
- human adenovirus 26 (non-replicating)
- Targets
- HIV-1 Env; HIV-1 Gag; HIV-1 Pol
- Originator
- Janssen Vaccines & Prevention
- Sponsor
- Johnson & Johnson
Names
Virus
- Role
- Vaccine vector
- Family
- Adenoviridae
- Virus
- human adenovirus 26
- Strain
- Ad26
- Replication
- non replicating
- Modifications
- non-replicating Ad26 encoding four mosaic HIV-1 antigens; given with an adjuvanted clade C plus mosaic gp140 protein boost
- Transgenes
- HIV-1 mosaic Env, HIV-1 mosaic Gag, HIV-1 mosaic Pol
- Route
- intramuscular
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (8)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT06205056 | Evaluation of Safety and Immunogenicity of Ad26.Mos4.HIV and CH505 TF chTrimer Combination in Healthy Adults | Recruiting | Phase 1 | 2024-01-30 | 2025-12 | 78 | Human Immunodeficiency Virus |
| NCT05769569 | Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission | Withdrawn | Phase 1 | 2023-09-01 | 2025-07-01 | 0 | HIV-1-infection |
| NCT04983030 | Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults | Completed | Phase 1/2 | 2022-04-01 | 2026-02-23 | 28 | Acquired Immunodeficiency Syndrome; HIV; Immunologic Deficiency Syndrome, Acquired; Retroviridae Infections; Sexually Transmitted Diseases, Viral |
| NCT03964415 | A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals | Completed | Phase 3 | 2019-10-31 | 2023-08-10 | 3900 | Healthy |
| NCT03307915 | A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment | Completed | Phase 1 | 2018-03-05 | 2021-11-05 | 25 | Human Immunodeficiency Virus |
| NCT03060629 | A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa | Terminated | Phase 2 | 2017-11-03 | 2022-02-02 | 2636 | HIV-1 |
| NCT02935686 | A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults | Completed | Phase 1/2 | 2017-03-31 | 2023-11-22 | 155 | Healthy |
| NCT02788045 | Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults | Completed | Phase 1/2 | 2016-07-08 | 2022-04-25 | 201 | Healthy |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42673762 | Quantifying how HIV-1 envelope sequence features impact vaccine efficacy in the HVTN 705/HPX2008 randomised trial in southern African women. | EBioMedicine | 2026 | name in abstract: Ad26.Mos4.HIV |
| PMID 40190112 | A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials. | Emerging microbes & infections | 2025 | cited by trial NCT03060629 |
| PMID 41314741 | Efficacy and safety of a mosaic HIV-1 vaccine regimen in men who have sex with men and transgender individuals (HVTN 706/HPX3002/Mosaico): a global, randomised, double-blind, placebo-controlled, phase 3 trial. | The lancet. HIV | 2025 | cited by trial NCT03964415 |
| PMID 39038477 | Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial. | The Lancet. Infectious diseases | 2024 | cited by trial NCT03060629 |
| PMID 39236556 | Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study. | EBioMedicine | 2024 | name in abstract: Ad26.Mos4.HIV |
| PMID 36348617 | Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study. | The Journal of infectious diseases | 2023 | cited by trial NCT02935686 |
| PMID 33010242 | Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study. | The lancet. HIV | 2020 | cited by trial NCT02788045 |
| PMID 30047376 | Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). | Lancet (London, England) | 2018 | cited by trial NCT03060629 |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| U19AI128751 | Project 2 | BETH ISRAEL DEACONESS MEDICAL CENTER | SCHUITEMAKER, HANNEKE | 2018–2022 | name in abstract: Ad26.Mos4.HIV |
Notes
Ad26 vector delivering four mosaic HIV-1 immunogens, given as four injections over a year with a clade C and mosaic gp140 protein boost in the last two doses. The phase 3 Mosaico trial (HVTN 706) was stopped in January 2023 for lack of efficacy. The related phase 2b Imbokodo regimen (HVTN 705) used Ad26.Mos.HIV, a different antigen set, which did not reach phase 3 and is not entered.
How to cite
Ad26.Mos4.HIV (AXP000174.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000174.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.